(3E)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3E)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid
• 化学式: C₁₈H₁₄N₄O₅S
• 分子量: 398.4
• InChiKey: OQANPHBRHBJGNZ-FYJGNVAPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  146
• 氢给体数：
  3
• 氢受体数：
  9

文献信息

• BIS-AROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION
  申请人：Pelcman Benjamin

  公开号：US20100286215A1

  公开（公告）日：2010-11-11

  There is provided compounds of formula (I): wherein Y, ring A, D 1 , D 2 , D 3 , L 1 , Y 1 , L 2 , Y 2 , L 3 and Y 3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C 4 synthase is desired and/or required, and particularly in the treatment of a respiratory disorder and/or inflammation.

  提供了具有以下式（I）的化合物：其中Y、环A、D1、D2、D3、L1、Y1、L2、Y2、L3和Y3的含义如描述中所示，并且其药学上可接受的盐，这些化合物在治疗需要或者期望抑制白三烯C4合酶的疾病中非常有用，特别是在治疗呼吸道疾病和/或炎症方面。
• [EN] PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIMIDINE-2,4-DIAMINE EN TANT QU'INHIBITEURS DE KINASE
  申请人：CELLZOME LTD

  公开号：WO2013092854A1

  公开（公告）日：2013-06-27

  The present invention relates to compounds of formula (I) wherein X, R, Y0, T0A, T0B have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immuno logically-mediated diseases. The invention also relates to pharmaceutical compositions including said compoundsand their use as medicaments.

  本发明涉及式(I)的化合物，其中X、R、Y0、T0A、T0B的含义如描述和权利要求中所述。所述化合物可用作JAK抑制剂，用于治疗或预防免疫、炎症、自身免疫、过敏性疾病和免疫学介导的疾病。该发明还涉及包括所述化合物的药物组合物及其作为药物的用途。
• [EN] TARGETING DIAZO PRODRUGS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES<br/>[FR] CIBLAGE DE PROMÉDICAMENTS DIAZO POUR LE TRAITEMENT DE MALADIES GASTRO-INTESTINALES
  申请人：TRINITY COLLEGE DUBLIN

  公开号：WO2009003970A1

  公开（公告）日：2009-01-08

  Provided herein are compounds, compositions and methods for decreasing NFkB DNA-binding activity in a patient comprising administering of a therapeutically effective amount of a compound or composition of the application to the patient to reduce, alleviate or treat various gastrointestinal diseases, such as inflammatory bowel disease (IBD).

  本文提供了一种减少患者NFkB DNA结合活性的化合物、组合物和方法，包括向患者施用本申请的化合物或组合物的治疗有效量，以减少、缓解或治疗各种胃肠疾病，如炎症性肠病（IBD）。
• [EN] TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS<br/>[FR] ADMINISTRATION CIBLÉE D'UN MÉDICAMENT FAISANT APPEL À DES COUPLEURS FONDÉS SUR L'AFFINITÉ
  申请人：INVICTUS ONCOLOGY PVT LTD

  公开号：WO2015148126A1

  公开（公告）日：2015-10-01

  The current invention discloses targeted drug delivery conjugates comprising a targeting moiety linked to a drug via a molecule having an affinity for the targeting moiety. Typically, the conjugate comprises a targeting ligand and a molecule of interest, e.g., a therapeutic agent. The targeting ligand and the molecule of interest are linked to each other via an affinity ligand. The affinity ligand is further covalently or non-covalently linked to a drug or therapeutic agent. The drug can be modified to make it more soluble and so that it cleaves from the linking molecule at the target site.

  当前的发明揭示了包括通过具有与靶向基团亲和力的分子连接到药物的靶向药物传递共轭物。通常，该共轭物包括一个靶向配体和一个感兴趣的分子，例如，一个治疗剂。靶向配体和感兴趣的分子通过一个亲和配体相互连接。该亲和配体进一步以共价或非共价方式连接到药物或治疗剂。药物可以被修改以使其更溶解，并使其在靶点处从连接分子中解离。
• [EN] PYRIDINE COMPOUNDS AND AZA ANALOGUES THEREOF AS TYK2 INHIBITORS<br/>[FR] COMPOSÉS DE PYRIDINE ET LEURS ANALOGUES AZA EN TANT QU'INHIBITEURS DE TYK2
  申请人：CELLZOME LTD

  公开号：WO2012062704A1

  公开（公告）日：2012-05-18

  The present invention relates to compounds of formula (I), wherein R1 to R3, X1, X2 have the meaning as cited in the description and the claims. Said compounds are useful as TYK2 inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds as well as their use as medicaments.

  本发明涉及式(I)的化合物，其中R1至R3，X1，X2的含义如描述和权利要求中所述。所述化合物可用作TYK2抑制剂，用于治疗或预防免疫、炎症、自身免疫、过敏性疾病和免疫介导性疾病。该发明还涉及包括所述化合物的药物组合物，以及它们作为药物的用途。